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Abstract
Background: Nitric oxide (NO) synthesis has been described in several circumventricular and hypothalamic
structures in the central nervous system that are implicated in mediating central angiotensin-II (ANG-II) actions
during water deprivation and hypovolemia. Neuroendocrine and cardiovascular responses, drinking behavior, and
urinary excretions were examined following central angiotensinergic stimulation in awake freely-moving rats
pretreated with intracerebroventricular injections of Nω-nitro-L-arginine methyl ester (L-NAME, 40 μg), an inhibitor
of NO synthase, and L-arginine (20 ug), a precursor of NO.
Results: Injections of L-NAME or ANG-II produced an increase in plasma vasopressin (VP), oxytocin (OT) and atrial
natriuretic peptide (ANP) levels, an increase in water and sodium intake, mean arterial blood pressure and sodium
excretion, and a reduction of urinary volume. L-NAME pretreatment enhanced the ANG-II response, while
L-arginine attenuated VP and OT release, thirst, appetite for sodium, antidiuresis, and natriuresis, as well as pressor
responses induced by ANG-II.
Discussion and conclusion: Thus, the central nitrergic system participates in the angiotensinergic responses
evoked by water deprivation and hypovolemia to refrain neurohypophysial secretion, hydromineral balance, and
blood pressure homeostasis.
Background
Central injections of L-NAME or ANG-II produced an
increase in plasma vasopressin (VP), oxytocin (OT) and
atrial natriuretic peptide (ANP) levels, an increase in
water and sodium intake, mean arterial blood pressure
and sodium excretion, and a reduction of urinary
volume. L-NAME pretreatment enhanced the ANG-II
response, while L-arginine attenuated VP and OT
release, thirst, appetite for sodium, antidiuresis, and
natriuresis, as well as pressor responses induced by
ANG-II. Thus, the central nitrergic system participates
in the angiotensinergic responses evoked by water depri-
vation and hypovolemia by restrain neurohypophysial
secretion, hydromineral balance, and blood pressure
homeostasis. Nitric oxide (NO) is a lipophilic gas whose
synthesis is catalyzed by the enzyme nitric oxide
synthase (NOS) from the amino acid L-arginine [1,2]. In
the central nervous system, studies have shown that NO
plays an important role in neuroendocrine responses,
hydromineral balance, and cardiovascular regulation. It
m a ya l s om o d u l a t ev a s o p r e s s i n( V P )a n do x y t o c i n( O T )
release, water and sodium intake/excretion, and arterial
blood pressure homeostasis by osmotic and volemic
changes.
Water deprivation and hypovolemia stimuli induce a
marked activation of the renin-angiotensin system, that
increases the circulating level of angiotensin-II (ANG-II)
producing physiologic responses including drinking
behavior, salt appetite, maintenance of blood pressure,
and urinary excretions [3-5]. Intracerebroventricular
injection of ANG-II has been found to induce c-fos
expression in a restricted number of sites in the forebrain
and brainstem, such as neurons in the anterior region of
the third ventricle [6,7]. In the central nervous system of
rats, the subfornical organ (SFO) is the main site
* Correspondence: saad@foar.unesp.br
1Laboratory of Neuroendocrinology, Department of Physiology, School of
Medicine of Ribeirão Preto, University of Sao Paulo USP. Ribeirão Preto, Sao
Paulo, Brazil
Full list of author information is available at the end of the article
Reis et al. Behavioral and Brain Functions 2010, 6:64
http://www.behavioralandbrainfunctions.com/content/6/1/64
© 2010 Saad et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.responsible for mediating dipsogenic, natriorexigenic,
pressor effects [8], release of VP and OT into the sys-
temic circulation, and renal antidiuretic and natriuretic
effects of ANG-II [9-11].
T h ep r e s e n c eo fN O Sw a sd e s c r i b e di ns e v e r a lb r a i n
structures, including the circumventricular system, para-
ventricular (an important integrator of cardiovascular
function regulations), and the supraoptic nuclei, all
structures related to central angiotensinergic responses
[12,13]. These data suggest the possibility of an interac-
tion between NO and ANG-II in the control of body
fluid homeostase NO and ANG-II in the control of
body fluid homeostasis. In fact, the expression of NOS
gene was increased in the same structures related with
ANG-II actions after hypovolemia [14,15] and dehydra-
tion [16-18]. Furthermore, the inhibition of endogenous
NOS enhances drinking behavior and cardiovascular
responses induced by the central administration of ANG
II [4,19]. On the other hand, L-arginine, a precursor of
NO, as well as NO donors, were able to reduce VP and
OT release, water intake, blood pressure, diuretic and
natriuretic effects of central angiotensinergic stimulation
[4,20-22].
NO induces dipsogenic effect, neurohypophysial secre-
tion, and cardiovascular responses. Under basal normo-
volemic isosmotic conditions, NO tonically inhibits VP
and OT secretion into plasma [23,24]. Thus, in this
study we aimed to investigate the role of NO on VP and
OT secretion, water and sodium intake/excretion, and
blood pressure control following central ANG-II stimu-
lation in rats. This study indicates the variations of VP
and OT as the NO after angiotensinergic stimulation
corresponding to a hydromineral and cardiovascular
central regulation.
Materials and methods
Animals
Rats were housed in individual cages in a room with
controlled temperature (23 ± 2°C) and a 12-12 h light-
dark cycle (light on at 6:00 AM) with free access to food
pellets and tap water. All the experimental procedures
used in these studies were approved by the Ethical
Commission of Ethics in Animal Research of the School
of Medicine of Ribeirao Preto and by the Medical Ethics
Committee of the Paulista State University. Male Wistar
rats weighing ~300g were used for hormonal release
studies and male Holtzman rats (~280 g) were used for
the evaluation of water and saline intake, urinary excre-
tions and blood pressure recording experiments.
Surgical procedures
For all surgical procedures, Wistar rats were anesthetized
with 2.5% 2,2,2-tribromoethanol (Aldrich Chemical Co.,
USA; 1 ml/100 g body weight), IP) and Holtzman rats
were anesthetized with ketamine (80 mg/Kg body weight,
IM) and xylazine (7 mg/Kg body weight, IP). Five days
before experiments, stainless steel guide cannulas (10.0
mm long, 0.6 mm OD, 0.4 mm ID) were unilaterally
implanted into the right lateral cerebral ventricle accord-
ing to coordinates from the rat brain atlas [25]: 0.6 mm
caudal to the bregma, 1.5 mm lateral to the midline and
3.6 mm below the dura mater. The cannula was fixed to
the cranium using dental acrylic resin and two jeweler’s
screws. A 30 gauge metal wire filled the cannula at all
times except during the injections. After surgery, the rats
received a prophylactic injection of penicillin (50.000 U,
IM) and were allowed to recover for 5-6 days, during
which time they were handled daily and habituated to the
removal of the obturator of the guide cannula to mini-
mize stress during the experimental phase. The correct
placement of icv cannula in the lateral ventricle was con-
firmed at the end of the experiment by injection of Evans
Blue (2% in 0.5 μl) into the intracerebroventricular sys-
tem. Only animals with positive color in the intracerebro-
ventricular system were used in this study. Twenty-four
hours before the experiment, rats with an icv guide can-
nula were re-anesthetized with ketamine and xylazine
and a PE-10 polyethylene catheter connected to PE-50
tubing was inserted into the abdominal aorta through the
femoral artery for arterial pressure recording. Arterial
catheter was tunneled subcutaneously and exposed on
the back of the rat to allow access in unrestrained, freely-
moving rats.
Drugs
The drugs were injected into the lateral ventricle using a
Hamilton microsyringe connected by a PE-10 polyethy-
lene tube to a needle (30-gauge). L-NAME (Nω-nitro-L-
arginine methyl ester) and ANG-II (Asp-Arg-Val-Tyr-
Lle-His-Pro-Phe) were purchased from Sigma-Aldrich
(St. Louis, MO, USA) and dissolved in isotonic saline
(0.15 M NaCl). L-arginine was purchased from Tocris
(Ellisville, MO, USA) and dissolved in isotonic saline.
The drugs were injected in 0.5 μl volumes over a time
period of 30-60 seconds. All doses used in this study
were based on previous reports in the literature [4,26].
Experimental protocols
Twenty four hours before the experiments, all animals
were kept in the laboratory and on the day of experiments,
they received central administration of isotonic saline
(0.15 M NaCl) either alone or containing NOS inhibitor
(L-NAME, 40 μg) and NO precursor (L-arginine, 20 μg),
followed 10 minutes later, by icv injection of isotonic
saline with or without ANG-II (25 ng). The animals were
divided into three experimental protocols. The first proto-
col was designed for the measurement of plasma levels
of VP, OT, and ANP. Plasma was collected after the
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and ANP concentrations. Five minutes after icv ANG-II
injection, animals were decapitated and the trunk blood
was collected. The second protocol was designed for the
measurement of water and salt intake and sodium and
urine excretion. The rats were placed in metabolic cages
24 hours before the experiments and on the next day food
was removed. Water and 1.5% NaCl solution were offered
during a 60 minute period after ANG-II injection and
urinary excretion was collected 120 minutes after ANG-II
stimulation. The third protocol was designed to measure
arterial blood pressure (MAP). The animals were placed in
a test cage and MAP was recorded after 10 minutes rest-
ing baseline period and for 30 minutes after icv adminis-
tration of ANG-II. These protocol are the same for L-
NAME and L-arginine alone.
Determination of plasma hormone levels
Trunk blood was collected into cooled plastic tubes con-
taining heparin for the measurement of VP and OT and
into tubes containing EDTA (2 mg/ml of blood) and pro-
teolytic-enzyme inhibitors (20 μl of 1 mM phenylmethyl-
sulfonyl fluoride and 20 μlo f5 0 0μM pepstatin) for the
measurement of atrial natriuretic peptide (ANP). Blood
samples were centrifuged (1940 g for 20 min at 4°C) and
plasma was kept in a freezer at -70°C. For determination
of VP and OT, samples were extracted from 1 ml of
plasma with acetone and petroleum ether and ANP was
extracted from 1 ml of plasma using Sep-Pak C-18 car-
tridges (Waters Corporation, Milford, MA, USA). Plasma
levels of VP, OT, and ANP were measured by specific
radioimmunoassays as described previously [27-29]. The
assay sensitivity was 7.0 pg/ml for ANP, 0.9 pg/ml for
OT, and 0.8 pg/ml for AVP. The inter- and intra-assay
variations were 11.7% and 6% for ANP, 12.6% and 7% for
OT, and 17.5% and 3.3% for VP, respectively.
Fluid Intake and Urinary Excretion Measurements
Water and 1.5% NaCl intake were recorded using 0.5 ml
graduated burettes (expressed as ml/h). Urinary volume
was determined using 100 μl graduated tubes (expressed
as ml/2 h). Urinary sodium concentration (expressed as
μEq/2 h) was determined by an IL-143 flame spectro-
photometer (Instrumental Laboratories, USA).
Arterial blood pressure recordings
Direct mean arterial blood pressure (MAP) was recorded
in unanesthetized and conscious rats (expressed as
mmHg). The catheter was connected to a Statham (P23
Db) pressure transducer (Statham-Gould, Valley View,
OH) coupled to a multichannel recorder (PowerLab
Multirecord, USA), permitting the acquisition of cardio-
vascular data by computer.
Statistical analyses
The results are reported as means ± SEM. The data
were analyzed by Two-Way ANOVA followed by
Newman-Keuls post-hoc test. Statistical analysis was
performed using the SigmaStat program. Differences
were considered significant at P < 0.05.
Results
Effects of icv pretreatment with L-NAME and L-ARGININE
on VP, OT, and ANP plasma levels induced by central
angiotensinergic stimulation
Figures 1A, B and 1C show the plasma concentration of
VP, OT and ANP, respectively. A significant increase
(P < 0.05) in plasma VP, OT and ANP levels were
observed after L-NAME injection compared with the
control group (Saline + Saline) of rats. On the other
hand, no significant changes were observed in the plasma
concentrations of VP, OT and ANP after L-arginine
treatment.
The treatment with ANG-II increased (P < 0.05) VP,
OT and ANP plasma concentrations compared with the
control group. In rats stimulated by ANG-II, pretreat-
ment with L-NAME evoked an enhanced (P <0 . 0 5 )V P ,
OT and ANP plasma levels above the levels seen when
these reagents were injected separately. Conversely, pre-
treatment with L-arginine reduced (P <0 . 0 5 )t h e
response of VP and OT concentrations, but it did not
modify ANP plasma levels induced by ANG-II.
Effects of icv pretreatment with L-NAME and L-ARGININE
on water and sodium intake induced by central
angiotensinergic stimulation
Figures 2A and 2B show water and sodium chloride
intake, respectively. Significant increases (P <0 . 0 5 )i n
water and sodium chloride intake were observed after
icv injection of L-NAME compared with the control
group (Saline + Saline). On the other hand, no signifi-
cant effects were observed in water and sodium intake
after L-arginine injection.
Injection of ANG-II increased (P < 0.05) water and
sodium intake compared with the control group. Pre-
treatment with L-NAME in rats who received ANG-II
injection potentiated (P < 0.05) water and sodium chlor-
ide intake values to levels above those observed when the
peptide was injected individually. On the contrary, the
dipsogenic and natriorexigenic effects of ANG-II were
reduced (P < 0.05) by pretreatment with L-arginine.
Effects of icv pretreatment with L-NAME and L-ARGININE
on urinary volume and sodium excretion induced by
central angiotensinergic stimulation
Figures 3A and 3B show urinary volume and sodium
excretion, respectively. A significant decrease (P <0 . 0 5 )
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excretion were observed after injection of L-NAME
compared with the control group (Saline+Saline) of rats.
On the other hand, a reduction (P < 0.05) in the urinary
volume and an elevation (P < 0.05) in the sodium excre-
tion were observed in rats treated with L-arginine.
Treatment with ANG-II reduced (P <0 . 0 5 )u r i n a r y
volume and increased (P < 0.05) sodium excretion com-
pared with the control group. In rats stimulated with
ANG-II, those pretreated with L-NAME had higher (P <
0.05) antidiuresis and natriuresis than that observed
when the drugs were injected separately. On the
contrary, pretreatment with L-arginine did not modify
the urinary volume, although it blocked (P <0 . 0 5 )
the sodium excretion induced by angiotensinergic
stimulation.
Effects of icv pretreatment with L-NAME and L-ARGININE
on MAP induced by central angiotensinergic stimulation
Figure 4 shows the MAP response. A significant increase
(P < 0.05) in mean arterial pressure was observed after
icv injection of L-NAME compared with the control
group (Saline+Saline). On the other hand, no significant
effect was observed after L-arginine injection.
Injection of ANG-II increased (P <0 . 0 5 )M A Pc o m -
pared with the control group. Rats were pretreated with
Figure 1 A, B, C. Effects of pretreatments with isotonic saline
(0.9% NaCl), L-NAME (40 μg) or L-ARGININE (20 μg) in rats
submitted to central injection of ANG-II (26 ng) or isotonic
saline on plasma vasopressin (VP) (A), oxytocin (OT) (B), and
atrial natriuretic peptide (ANP) (C) secretion. Seven to nine
animals were used in each group. Differences among groups were
determined by Two-Way ANOVA followed by the Newman-Keuls
post test. Data are reported as means ± SEM. *P < 0.05 compared
to the control group (Saline + Saline). ￿P < 0.05 compared to the
Saline+L-ARGININE group.
#P < 0.05 compared to the Saline+L-
NAME group.
+P < 0.05 compared to the Saline+ANG-II group.
Figure 2 A, B. Effects of pretreatments with isotonic saline
(0.9% NaCl), L-NAME (40 μg) or L-ARGININE (20 μg) in rats
submitted to central injection of ANG-II (26 ng) or isotonic
saline on water (A) and sodium (B) intake. Eight to ten animals
were used in each group. Differences among groups were
determined by Two-Way ANOVA followed by the Newman-Keuls
post test. Data are reported as means ± SEM. *P < 0.05 compared
to the control group (Saline + Saline). ￿P < 0.05 compared to the
Saline+L-ARGININE group.
#P < 0.05 compared to the Saline+L-
NAME group.
+P < 0.05 compared to the Saline+ANG-II group.
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(P < 0.05) MAP values than those seen when ANG-II
and L-name were injected alone. On the contrary, the
MAP effect of ANG-II was abolished (P < 0.05) by pre-
treatment with L-arginine. After 30 minutes MAP was
restored to control values in all groups.
We founded that there are difference in the change in
AVP, OT, ANP plasma levels with L-NAME between
the saline and ANG-II groups.
Discussion
In the present study, we show that the endogenous inhi-
bition of central NO production by a single intra-
cerebroventricular injection of L-NAME promoted an
increase of plasma VP, OT, and ANP concentration,
MAP water and sodium appetite, and urinary volume
and sodium excretion. The effects of the central nitrer-
gic system on hydromineral imbalance in the literature
have been controversial, thus, in this study we investi-
gated the effects of NO precursor and NOS blocker
after central angiotensinergic stimulation.
Previous studies showed that L-NAME-induced VP,
OT, and ANP secretion was correlated with antidiuretic
and natriuretic effects [22]. The increase in ANP plasma
concentration may be a consequence of OT release [28].
Both hormones act on the kidney closing renal tubules
sodium channels and VP is related to water reabsorption
in the kidney [30,31]. Thus, our data show that the
reduction of central nitrergic tonus induced by NOS
blocker may be a result of the predominance of angio-
tensinergic pathways [19] that facilitate VP and OT
release.
We observed that L-NAME induced an increase in
MAP; other studies have shown that central treatment
with L-NAME increased MAP by reducing NO produc-
tion in the PVN, an important neural structure that pro-
jects to areas in the spinal cord controlling the
sympathetic nervous system [19,24]. This effect has
been ascribed to a neural component (sympathetic
nerve activity) that mediates the short latency and dura-
tion of pressor response. Microinjection of NOS blocker
directly into the PVN increased the discharges of renal
sympathetic nerves, elevating arterial blood pressure
[32]. In addition to the neural pathway, there is also a
humoral component (vasopressin) responsible for the
long duration and latency of the MAP response. The
effect of the NOS inhibitor may be mediated by periph-
eral effects of VP increasing blood pressure [24].
Figure 3 A, B. Effects of pretreatments with isotonic saline
(0.9% NaCl), L-NAME (40 μg) or L-ARGININE (20 μg) in rats
submitted to central injection of ANG-II (26 ng) or isotonic
saline on urinary volume (A) and sodium (B) excretion. Eight or
nine animals were used in each group. Differences among groups
were determined by Two-Way ANOVA followed by the Newman-
Keuls post test. Data are reported as means ± SEM. *P < 0.05
compared to the control group (Saline + Saline). ￿P < 0.05
compared to the Saline + L-ARGININE group.
#P < 0.05 compared to
the Saline+L-NAME group.
+P < 0.05 compared to the Saline+ANG-II
group.
Figure 4 Effects of pretreatments with isotonic saline (0.9%
NaCl), L-NAME (40 μg) or L-ARGININE (20 μg) in rats submitted
to central injection of ANG-II (26 ng) or isotonic saline on
mean arterial pressure (MAP). Eight to ten animals were used in
each group. Differences among groups were determined by Two-
Way ANOVA followed by the Newman-Keuls post test. Data are
reported as means ± SEM. *P < 0.05 compared to the control group
(Saline + Saline). *P < 0.05 compared to the control group (Saline
+Saline).
#P < 0.05 compared to the Saline+L-NAME group.
+P <
0.05 compared to the Saline+ANG-II group.
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homeostatic body fluid mechanisms necessary for the
maintenance of body fluid balance. The circumventricu-
lar organs, including the SFO and organum vasculosum
of the laminae terminalis (OVLT) and median preoptic
nucleus (MnPO) play an important role in the control
of thirst and sodium appetite [33]. In fact, SFO is the
main target for ANG-II to stimulate water and salt
intake, and it is also involved in the control of blood
pressure and neurohypophysial secretion [3,4]. It has
been postulated that ANG-II-induced water and sodium
intake can be explained, at least in part, by the increase
in VP content and neurotransmitter release from axons
of neurons onto the effector neurons of drinking
responses [34]. Treatment with V1 receptor antagonist
was shown to cause a marked decrease in water inges-
tion, but not sodium appetite, induced by angiotensiner-
gic activation [4].
It is also possible that circumventricular structures are
the site of NO action modulating drinking behavior.
Several studies have shown that NO is synthesized toni-
cally within the brain during conditions of normal water
balance because water and sodium intake increases
when endogenous production of NO is inhibited by
injection of L-NAME into and around the structures
surrounding third ventricle [20,26,35]. In this way, we
found that icv injection of L-NAME induces an increase
in water and sodium intake.
The results of our experiments show that central
angiotensinergic stimulation induced antidiuresis fol-
lowed by natriuresis associated with an increase of
plasma VP, OT, and ANP levels, with a concomitant
increase in mean arterial blood pressure and water and
sodium intake.
It was previously observed that icv injection of
L-NAME in combination with ANG-II enhanced VP
and OT secretion [22]. In agreement with these studies,
our results show that central pretreatment with
L-NAME in rats stimulated with ANG-II can induce a
further enhancement not only the VP and OT but also
ANP plasma levels with a concomitant increase in the
antidiuretic and natriuretic effects. The pressor effect of
central ANG-II stimulation was also modulated by
L-NAME. There was an initial increase in pressor
response within 5 minutes and a prolonged delayed
response at 30 minutes [19,24]. In addition, these data
show that angiotensinergic stimulation in rats pretreated
with L-NAME had potentiated arterial blood pressure
and water and sodium intake. Our findings are consis-
tent with other studies, which also showed that central
inhibition of NOS enhances ANG-II-induced thirst and
sodium appetite [20,26].
In an attempt to elucidate the role of NO on hydromin-
eral, neuroendocrine, and cardiovascular regulation, we
also used L-arginine, a precursor of NO, prior to ANG-II
stimulation. Our data showed that plasma VP and OT
concentration, dipsogenic and natriorexigenic effects,
blood pressure, and antidiuretic and natriuretic effects
induced by ANG-II were reduced by central pretreatment
with L-arginine. It was reported that L-arginine had an
antidipsogenic effect when administered centrally to rats
deprived of water or stimulated by ANG-II [21]. Other
NO donors used in the literature also indicated that the
nitrergic system exerts an inhibitory effect on ANG-II-
induced VP and OT release and blood pressure
[20,22,35]. Therefore, taken together, the present results
suggest the inhibitory action of NO system on the effects
of ANG-II on neuroendocrine responses, hydromineral
balance and blood pressure maintenance.
Besides the central activation of the renin-angiotensin
system during hemorrhage and water deprivation, these
conditions also evoke an up regulation of NOS gene
expression in the circumventricular organs and hypotha-
lamic structures [14-18]. Moreover, systemic or icv infu-
sion of ANG-II promoted an increase of NOS activation
and expression in the PVN, SON, SFO, MnPO and
OVLT [36-39].
We can hypothesize that there is an interaction
between angiotensinergic and nitrergic system in the
brain which is required to establish the body fluid
homeostasis. ANG-II stimulates NO production, which
in turn, counterbalances changes in the VP and OT
secretion, blood pressure and water and sodium intake
to maintain neurohypophysial hormone store during
chronic hypovolemia and dehydration.
The mechanism by which NO can inhibit angioten-
sin effects is not well understood. Reports in the litera-
ture have suggested that NO increases the release of
g-aminobutyric acid (GABA), as shown that bicuculline
(GABAergic antagonist), inhibited the neuroendocrine
action of NO in the PVN and SON neurons [40-42].
Thus, NO can either reach through indirectly presy-
naptic neurons in the circumventricular organs or
directly postsynaptic PVN and SON neurons, increas-
ing local activation of a GABAergic inhibitory system.
Conclusion
These results revealed that the endogenous central
nitrergic system could influence the ANG-II action in
the brain, decreasing neural inputs involved with the
neuroendocrine, behavioral, and cardiovascular struc-
tures related to the control of osmotic and volemic
homeostasis.
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